Antitrust Concerns Won't Derail $160B Pfizer-Allergan Deal
Pfizer's $160 billion bid to acquire Irish drugmaker Allergan will surely attract considerable government attention, but despite its eye-popping size, antitrust issues are unlikely to fell the deal given the way...To view the full article, register now.
Already a subscriber? Click here to view full article